Jedd Wolchok, MD, PhD
"Research means more hope for all patients in the future based on the best cutting edge science."
Dr. Wolchok is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics Service, Attending Physician at Memorial Sloan-Kettering Cancer Center (MSK) with an expertise in the treatment of metastatic melanoma. He received his undergraduate degree from Princeton University and both M.D and Ph.D. from New York University, where he also fulfilled his residency program. He completed his fellowship at MSK and remained on faculty with an appointment in the Melanoma and Immunotherapeutics Service, which he now leads. Dr. Wolchok has helped establish MSK as a leader in the discovery and treatment of cancers with novel immunotherapies. Dr. Wolchok was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma and recently designed and led a global phase 3 trial of combined checkpoint blockade for melanoma. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring innovative immunotherapeutic strategies in laboratory models and as a principal investigator in numerous pivotal clinical trials. In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies and has become a model for similar efforts by other major cancer centers throughout the world.
Dr. Wolchok is a six-time MRA-funded investigator, member of the MRA Medical Advisory Panel, and member of the MRA Grant Review Committee.
Without you, melanoma research can't happen. Learn more about clinical trials.
Please support MRA's mission to end death and suffering due to melanoma. 100% of your donation will go directly to funding innovative melanoma research, without any overhead, admin, or fundraising expenses.
